The present invention relates generally to methods for treating mammalian tissue, to subcutaneous adipose tissue treatment methods, and particularly to those involving cooling of the tissue.
Excess body fat increases the likelihood of developing various types of diseases such as heart disease, high blood pressure, osteoarthrosis, bronchitis, hypertension, diabetes, deep-vein thrombosis, pulmonary emboli, varicose veins, gallstones, hernias, and several other conditions.
In addition to being a serious health risk, excess body fat can also detract from personal appearance and athletic performance. For example, excess body fat can form cellulite, which causes an “orange peel” effect at the surface of the skin. Cellulite forms when subcutaneous fat protrudes into the dermis and creates dimples where the skin is attached to underlying structural fibrous strands. Cellulite and excessive amounts of fat are often considered to be unappealing. Thus, in light of the serious health risks and aesthetic concerns associated with excess fat, an effective way of controlling excess accumulation of body fat is urgently needed.
Liposuction is a method for selectively removing body fat to sculpt a person's body. Liposuction is typically performed by plastic surgeons and dermatologists using specialized surgical equipment that mechanically removes subcutaneous fat cells via suction. One drawback of liposuction is that it is a serious surgical procedure, and the recovery may be painful. Liposuction can have serious and occasionally even fatal complications. In addition, the cost for liposuction is usually substantial.
Conventional non-invasive treatments for removing excess body fat typically include topical agents, weight-loss drugs, regular exercise, dieting, or a combination of these treatments. One drawback of these treatments is that they may not be effective or even possible under certain circumstances. For example, when a person is physically injured or ill, regular exercise may not be an option. Similarly, weight-loss drugs or topical agents are not an option when they cause an allergic or negative reaction. Furthermore, fat loss in selective areas of a person's body cannot be achieved using general or systemic weight-loss methods.
Other non-invasive treatment methods include applying heat to a zone of subcutaneous lipid-rich cells. U.S. Pat. No. 5,948,011 discloses altering subcutaneous body fat and/or collagen by heating the subcutaneous fat layer with radiant energy while cooling the surface of the skin.
Another method of reducing subcutaneous fat cells is to cool the target cells as disclosed in U.S. Patent Publication No. 2003/0220674 or in U.S. Patent Publication No. 2005/0251120, the entire disclosures of which are incorporated herein. These publications disclose, among other things, reducing the temperature of lipid-rich subcutaneous fat cells to selectively affect the fat cells without damaging the cells in the epidermis. Although these publications provide promising methods and devices, several improvements for enhancing the implementation of these methods and devices would be desirable.
In medicine, ischemia is a restriction in blood supply, generally due to factors in the blood vessels, with resultant damage or dysfunction of tissue. Since oxygen is mainly bound to hemoglobin in red blood cells, insufficient blood supply causes tissue to become hypoxic, or, if no oxygen is supplied at all, anoxic. This can cause necrosis and cell death. Ischemia is a feature of heart diseases, transient ischemic attacks, cerebrovascular accidents, ruptured arteriovenous malformations, and peripheral artery occlusive disease. Tissues that are especially sensitive to inadequate blood supply include the heart, the kidneys, and the brain.
Restoration of blood flow after a period of ischemia is generally recognized to actually be more damaging than the ischemia itself. The absence of oxygen and nutrients from blood creates a condition in which the restoration of circulation results in inflammation and oxidative damage from the oxygen (i.e., reperfusion injury) rather than restoration of normal function. Reintroduction of oxygen also causes a greater production of damaging free radicals. With perfusion injury, necrosis can be greatly accelerated.
In one aspect, the present invention provides methods and devices that use ischemia-reperfusion injury to reduce or eliminate fat cells in the human body. Although it is generally considered desirable to minimize ischemia-reperfusion injury to cells in the human body, it is believed, while not intending to be bound by theory, that it is beneficial to effect ischemia-reperfusion injury in adipose tissue, thus enhancing adipose tissue necrosis or apoptosis.
In certain embodiments, the present invention thus provides methods for affecting a region of a subject's body, comprising exposing an epidermal layer in said region to a cooling element under conditions effective to cool subcutaneous adipose tissue in said region; and increasing the rate of blood flow to the cooled tissue by exposing the tissue to an energy source.
In another embodiment, the invention provides methods of treating subcutaneous adipose tissue in a region of a subject's body, comprising exposing said region to a cooling element under conditions effective to cool said tissue; and stimulating reperfusion in the cooled tissue by exposing the tissue to an energy source to increase the blood flow rate to the cooled tissue.
The present invention also provides methods of treating subcutaneous adipose tissue in a region of a subject's body, comprising exposing said region to a cooling element under conditions effective to cool said tissue; and causing an ischemia-reperfusion injury to the cooled tissue by exposing the tissue to an energy source to increase the blood flow rate to the cooled tissue.
In still another embodiment, the present invention provides cooling methods for selective reduction of lipid-rich cells in a region of a human subject's body, comprising applying a cooling element proximal to the subject's skin to reduce the temperature within a local region containing the lipid-rich cells sufficiently to selectively reduce the lipid-rich cells of said region, and concurrently therewith maintain the subject's skin at a temperature wherein non-lipid-rich cells proximate to the cooling element are not reduced; and subsequent to applying a cooling element, applying an energy source to the cooled tissue to thereby increase a rate of blood flow to the cooled tissue.
In another embodiment, the present invention provides methods for selective reduction of lipid-rich cells in a region of a human subject's body, comprising selectively causing vasoconstriction in adipose tissue; and subsequently stimulating reperfusion by applying an energy source to thereby increase blood flow to the region.
In still another embodiment, the present invention provides methods for selectively creating ischemia in lipid-rich cells in a region of a human subject's body, and subsequently stimulating reperfusion by applying an energy source to thereby increase the blood flow.
The figures are provided by way of example and are not intended to be limiting.
In one embodiment, the present invention provides methods for affecting a region of a subject's body, comprising exposing an epidermal layer in said region to a cooling element under conditions effective to cool subcutaneous adipose tissue in said region; and increasing the blood flow rate to the cooled tissue by exposing the tissue to an energy source.
In certain embodiments, the methods further comprise cycling at least one of the steps of exposing said region to a cooling element and increasing blood flow. For example, after a cycle of exposing said region to a cooling element and increasing blood flow, a step of exposing said region to a cooling element could be repeated. Alternatively, a step of increasing blood flow could be added.
In certain embodiments, the methods of the invention further comprise increasing vasoconstriction in the adipose tissue. This can be achieved by various mechanical, chemical means or certain cooling conditions. Certain drugs can be administered orally or injected into the adipose tissue to increase vasoconstriction. Epinephrine is an example of one vasoconstrictive drug that is commonly injected. Other examples include norepinephrine, catecholamines, epinephrine isoproterenol, dopamine, ephedrine, phenylephrine, amphetamine, metraminol, methoxamine, ergot alkaloids, ergonovine, methylergonavine, methysergide, and ergotamine. A mechanical means for increasing vasoconstriction would be by application of pressure to the region.
For purposes of this specification, “affecting” means affecting, disrupting, shrinking, disabling, destroying, removing, killing, or otherwise being altered. As mentioned above, cooling subcutaneous adipose tissue may result in disruption and eventual death of the adipocytes.
The term “subject,” as used herein, includes any animal having blood, adipose tissue, and an epidermis. In preferred embodiments, the subject is a human or some other mammal, even more preferably a non-infant human.
The term “temperature control element” refers to any structure that is able to effect an increase or reduction in temperature of an area or object of interest. A temperature control element that effects a reduction in temperature is, thus, a “cooling element.” In one embodiment, the temperature control element is actively cooled or heated, as with a fluid bath or the Peltier (thermoelectric) elements that are known in the art to create cold and warm surfaces dependent upon the application of voltage.
Depending on the type of fluids circulated through the applicator 16, a wide temperature range can be achieved at the applicator 16. The applicator 16 can be formed from a variety of thermoconductive materials, including copper, aluminum, or alloys, and is applied to a subject's epidermis. Alternatively, the applicator 16 could be formed from a relatively thin layer of nonconductive material, such as urethane. A fluid control unit 18 is disposed between the baths and the applicator to control the applicator temperature.
Referring to
The system 100 can further include a cooling unit 106 and supply and return fluid lines 108a-b connecting the cooling device 104 to the cooling unit 106. The cooling unit 106 can remove heat from a coolant to a heat sink and provide a chilled coolant to the cooling device 104 via the fluid lines 108a-b. Examples of the circulating coolant include water, glycol, synthetic heat transfer fluid, oil, a refrigerant, and any other suitable heat conducting fluid. The fluid lines 108a-b can be hoses or other conduits constructed from polyethylene, polyvinyl chloride, polyurethane, and other materials that can accommodate the particular circulating coolant. The cooling unit 106 can be a refrigeration unit, a cooling tower, a thermoelectric chiller, or any other device capable of removing heat from a coolant. Alternatively, a municipal water supply (i.e., tap water) can be used in place of the cooling unit.
The cooling device 104 includes a plurality of thermoelectric cooling elements, such as Peltier-type thermoelectric elements, which can be individually controlled to create a custom spatial cooling profile and/or a time-varying cooling profile. The system 100 can further include a power supply 110 and a processing unit 114 operatively coupled to the cooling device 104. In one embodiment, the power supply 110 can provide a direct current voltage to the thermoelectric cooling device 104 to effectuate a heat removal rate from the subject 101. The processing unit 114 can monitor process parameters via sensors (not shown) placed proximate to the cooling device 104 through power line 116 to adjust the heat removal rate based on the process parameters. The heat transfer rate can be adjusted to maintain constant process parameters. Alternately, the process parameters can vary either spatially or temporally. The processing unit 114 can be in direct electrical communication through line 112, or alternatively, may be connected via a wireless communication: Alternatively, the processing unit 114 can be preprogrammed to provide a spatially distributed cooling profile and/or a time-varying cooling profile. The processing unit 114 can include any processor, Programmable Logic Controller, Distributed Control System, and the like.
In another aspect, the processing unit 114 can be in electrical communication with an input device 118, an output device 120, and/or a control panel 122. The input device 118 can include a keyboard, a mouse, a touch screen, a push button, a switch, a potentiometer, and any other device suitable for accepting user input. The output device 120 can include a display screen, a printer, a medium reader, an audio device, and any other device suitable for providing user feedback. The control panel 122 can include indicator lights, numerical displays, and audio devices. In alternative embodiments, the control panel 122 can be contained on the cooling device 104. In the embodiment shown in
The cooling device 104 is shown in a first relatively flat configuration in
One advantage of the plurality of rotatable heat exchanging surfaces is that the arcuate shape of the cooling device may concentrate the heat transfer in the subcutaneous region. For example, when heat exchanging surfaces are rotated about a body contour of a subject, the arcuate shape can concentrate heat removal from the skin.
The control system housing 202 can house a processing unit for controlling the cooling device 104 and/or fluid lines 108a-b and/or electrical power and communication lines. The control system housing 202 includes a harness port 210 for electrical and supply fluid lines (not shown for purposes of clarity). The control system housing 202 can further be configured to serve as a handle for a user of the cooling device 104. Alternatively, the processing unit may be contained at a location other than on the cooling device.
As shown in
The retention devices 208a and 208b are each shown as tabs 214, each having a slot 216 therein for receiving a band or elastomeric strap (not shown for purposes of clarity) to retain the cooling device 104 in place on a subject 101 during treatment. Alternatively, the cooling device may not contain any attached retention device and may be held in place by hand, may be held in place by gravity, or may be held in place with a band, elastomeric strap, or non-elastic fabric (e.g., nylon webbing) wrapped around the cooling device 104 and the subject 101.
In an alternate embodiment, the device may be a device for applying pressure, or otherwise inducing vasoconstriction, rather than a cooling device.
As shown in
The cooling elements 302a-g can be affixed to the flexible substrate 350, or may be embedded in the flexible substrate 350. The flexible substrate 350 can be constructed from polymeric materials, elastomeric materials, and/or other suitable materials. The flexible substrate 350 can further be an elastomer such as silicone or urethane or can be a fabric, such as nylon. The flexible substrate 350 can also be a thin polymer such as polypropylene or ABS. The example of the flexible substrate 350 shown in
As designed, the interface members and cooling elements protect the thermoelectric coolers while maintaining good heat transfer between the thermoelectric coolers and the skin. The interface members are sized such that they do not present a significant thermal mass. In one design, each thermoelectric cooler could be 1″×1.5″. The interface member or aluminum plate could also be 1″×1.5″ with a thickness of 0.04″. If the thermoelectric coolers' cooling power is approximately 10 W, which is appropriate based on the heat flux expected to conduct from the skin, then the aluminum plate would cool from an ambient temperature of 20° C. to a treatment temperature of −10° C. in about 7 seconds. The change in internal energy of the plate is described by the following equation:
ΔE=ρ·V·C·ΔT
where ΔE is the change in internal energy, ρ is the material density, V is the material volume, C is the heat capacity of the material, and ΔT is the temperature change. In the problem described above, the volume of the aluminum plate is V=1 in×1.5 in×0.04 in or 0.06 in3 (9.8×10-7 m3). For a typical grade of aluminum, C.°=875 J/kg*° C. and ρ=2770 kg/m3.
Solving the equation using these constants:
ΔE=2770 kg/m3*9.8−10-7m3*875 J/kg*° C.*30° C.=71.3 J
If the thermoelectric coolers have a cooling power of 10 W, then 71.3 J could be removed from the aluminum plate in 7.1 seconds, as is shown in the calculation below:
71.3 J/(10 J/second)=7.13 seconds
A small gap or recess in the frame at the skin surface may be included in one embodiment. Prior to applying the cooling device to the skin, a thermally conducting fluid or coupling agent can be applied to the device and to the skin to minimize contact resistance and increase heat transfer between the cooling device and the skin. This coupling agent will fill the gap in the cooling device and allow for limited lateral conduction between the thermoelectric coolers' plates. This will create a more uniform temperature gradient across the surface area of the skin when the cooling is applied to the skin.
The lipid-rich cells can be affected by disrupting, shrinking, disabling, destroying, removing, killing, or otherwise being altered. Without being bound by theory, selectively affecting lipid-rich cells is believed to result from localized crystallization of lipids at temperatures that do not induce crystallization in non-lipid-rich cells. The crystals can disrupt or alter the bi-layer membrane of lipid-rich cells to selectively damage these cells. Thus, damage of non-lipid-rich cells, such as dermal cells, can be avoided at temperatures that induce crystal formation in lipid-rich cells. Cooling is also believed to induce lipolysis (e.g., fat metabolism) of lipid-rich cells to further enhance the reduction in subcutaneous lipid-rich cells. Vasoconstriction by means other than cooling are contemplated by the present invention. For example, pressure or administration of certain drugs may be employed to cause ischemia.
The coupling agent may be applied to the skin or to the interface member to provide improved thermal conductivity. The coupling agent may include polypropylene glycol, polyethylene glycol, propylene glycol, and/or glycol. Glycols, glycerols, and other deicing chemicals are efficient freezing-point depressants and act as a solute to lower the freezing point of the coupling agent. Propylene glycol is one exemplary component of deicer or non-freezing coupling agents. Other components include polypropylene glycol (PPG), polyethylene glycol (PEG), polyglycols, glycols, ethylene glycol, dimethyl sulfoxide, polyvinyl pyridine, calcium magnesium acetate, sodium acetate, ethanol and/or sodium formate. The coupling agent preferably has a freezing point in the range of −40° C. to 0° C., more preferably below −10° C. as further described in U.S. Provisional Application 60/795,799, entitled Coupling Agent For Use With a Cooling Device For Improved Removal of Heat From Subcutaneous Lipid-Rich Cells, filed on Apr. 28, 2006, herein incorporated in its entirety by reference.
In operation, the input module 944 accepts an operator input, such as process setpoint and control selections, and communicates the accepted information or selections to other components for further processing. The database module 946 organizes records, including operating parameters 954, operator activities 956, and alarms 958, and facilitates storing and retrieving of these records to and from a database 952. Any type of database organization can be utilized, including a flat file system, hierarchical database, relational database, or distributed database, such as provided by a database vendor such as Oracle Corporation, Redwood Shores, Calif.
The process module 948 generates control variables based on sensor readings 960, and the output module 950 generates output signals 962 based on the control variables. For example, the output module 950 can convert the generated control variables from the process module 948 into 4-20 mA output signals 962 suitable for a direct current voltage modulator. The processor 942 optionally can include the display module 951 for displaying, printing, or downloading the sensor readings 960 and output signals 962 via devices such as the output device 120. A suitable display module 951 can be a video driver that enables the processor 942 to display the sensor readings 960 on the output device 120.
One interesting feature of a thermoelectric cooler is that if the polarity of the applied voltage is reversed, the cold side becomes warm and the warm side becomes cold. In this way, the thermoelectric cooler may be employed to increase the blood flow rate and stimulate reperfusion in the cooled tissue. This would cause ischemia-reperfusion injury and improve the results achieved by the methods described in U.S. Patent Publication No. 2003/0220674 and in U.S. Patent Publication No. 2005/0251120.
Regardless of the cooling element type, the cooling element can be maintained at an average temperature between about −30° C. and about 35° C., preferably from about −20° C. to about 20° C., more preferably from about −20° C. to about 10° C., more preferably from about −15° C. to about 5° C., more preferably from about −10° C. to about 0° C. In one embodiment, the region is exposed to the cooling element from about 2 min to about 60 min, or preferably from about 5 min to about 30 min.
After cooling has been effected or vasoconstriction otherwise induced, the tissue of interest is exposed to an energy source to increase blood flow. The term “energy source” refers to any known form of energy that would increase blood flow in a subject, either by inflammation or other mechanisms. As will be recognized, the energy source can be the same device used to effect cooling (as, for example, by changing the temperature profile of a fluid bath or by reversing polarity on the applied voltage of a thermoelectric cooler) or a different device. Energy sources according to the invention can supply electromagnetic energy (e.g., light, radiofrequency), thermal energy (e.g., heat) and/or mechanical energy (e.g., physical contact, friction, vibration, sound waves). In preferred embodiments, the energy source causes the blood flow rate to increase more rapidly than would occur without the energy source.
The energy source can, for example, be a capacitively coupled RF device such as those in which a power source provides energy to an RF generator and then to at least one RF electrode. An electronic measuring system measures current, voltage, and temperature via thermal sensors. The present invention utilizes an electronic measuring system driven by a controller, such as a computer with appropriate software. Various feedback or monitoring systems attached to the controller include ultrasonic, thermal, or impedance monitors. Current and voltage are used to calculate impedance. The output for these monitors is used by the controller to control the delivery of RF power. The amount of RF energy delivered controls the amount of RF power.
In one embodiment, the RF energy is provided by an RF electrode coated with dielectric material. The use of dielectric coating produces a more uniform impedance throughout the electrode and causes a more uniform current to flow through the electrode. The resulting effect minimizes edge effects around the edges of the electrode. It is desirable to have the electrical impedance of the dielectric layer to be higher than that of the subject tissue. In various embodiments, the impedance of layer 32′ at the operating frequency, can be in the range of 200 Ω/cm2 or greater. Suitable materials for a dielectric coating include, but are not limited to, TEFLON, silicon nitride, polysilanes, polysilazanes, polyimides, KAPTON, antenna dielectrics and other dielectric materials well known in the art.
In one embodiment, one or more RF electrodes are connected to an RF generator. The temperature of the tissue or of RF electrode is monitored, and the output power of energy source adjusted accordingly. The system can be a closed- or open-loop system to switch power on and off, as well as modulate the power. A closed-loop system utilizes a microprocessor to serve as a controller to monitor the temperature, adjust the RF power, analyze the result, feed back the result, and then modulate the power. More specifically, a controller governs the power levels, cycles, and duration that the radiofrequency energy is distributed to the individual electrodes to achieve and maintain power levels appropriate to achieve the desired treatment. In one embodiment, the controller is an INTEL PENTIUM microprocessor; however it will be appreciated that any suitable microprocessor or general purpose digital or analog computer can be used to perform one or more of the functions of controller.
With the use of sensor and feedback control system skin or other tissue adjacent to the RF electrode can be maintained at a desired temperature for a selected period of time without causing a shut-down of the power circuit to electrode due to the development of excessive electrical impedance at electrode or adjacent tissue. Current and voltage can be measured by sensors, and used to calculate impedance and power. A control signal is generated by controller that is proportional to the difference between an actual measured value, and a desired value. The control signal is used by power circuits to adjust the power output in an appropriate amount in order to maintain the desired power delivered at respective RF electrodes.
In a similar manner, temperatures detected at a sensor provide feedback for maintaining a selected power. A control signal is generated by a controller that is proportional to the difference between an actual measured temperature and a desired temperature. The control signal is used by power circuits to adjust the power output in an appropriate amount in order to maintain the desired temperature delivered at the sensor.
Examples of methods utilizing RF on a subject are disclosed in U.S. Pat. Nos. 6,413,255 and 5,948,011, the entire disclosures of which are incorporated herein.
Alternatively, the energy source can be vibrational, and delivered by a conventional vibrating device. Such vibratory massagers are known to increase blood circulation and perfusion. Representative devices include the Endermologie ES1 device (LPG Systems, Valence, France), VelaSmooth system (Syneron Inc, Richmond Hill, Ontario, Canada), and TriActive Laserdermology system (Cynosure Inc, Chelmsford, Mass., USA).
Alternatively, the energy source can be acoustic, and delivered by ultrasound transducers. Ultrasound energy is well known to those skilled in the art to be capable of heating tissue. Treatment devices can include a high intensity focused ultrasound (HIFU) system—in particular, a system with a plurality of independently controlled multiple beam transducer elements that are capable of being focused at the treatment depths below the skin surface. A HIFU transducer comprises an army of transducer elements. Each transducer element comprises a piezoelectric element, solid coupling element, and focusing lens. The transducer elements may span treatment depths including 0.35 to 3.5 cm. For example, five transducer elements may have focal points of 0.5, 0.8, 1.2, 1.9, and 3.0 cm, with correspondingly operate frequencies of 12, 9, 7, 5.5, and 4 MHz, respectively. It should be noted that the transducer may comprise different numbers of transducer elements.
The HIFU transducer supplies a predetermined amount of ultrasonic energy per unit distance traveled (not per unit time) for each treatment region and sensors that detect cavitation and boiling of the fat tissue. The HIFU transducer can be controlled to determine the desired temperature through feedback mechanisms. For example, a monitored Doppler dynamic sound caused by cavitation or boiling may be used as an indicator to set a power level outputted by the transducer in the HIFU system. Examples of methods utilizing HIFU on a subject are disclosed in U.S. Patent Publication No. 2006/0122509, U.S. Patent Publication No. 2005/0154431, and U.S. Patent Publication No. 2004/0039312, the entire disclosures of which are incorporated herein.
In one embodiment, the energy source is applied such that the region is warmed to about normal body temperature. Alternatively, the energy source is applied such that the region is warmed to above normal body temperature. Alternatively, the energy source is applied such that the region is warmed to a temperature warmer than the temperature of the previously cooled lipid-rich cells, at least enough to stimulate reperfusion.
The amount of time that the energy source is applied typically depends on the energy source itself. For example, depending on the source, the energy is applied for from about 1 sec to about 30 min. Preferably, the energy is applied for from about 1 sec to about 15 min. Skilled artisans are aware of the variables to consider when applying energy to a subject.
In certain embodiments, energy, such as capacitively coupled radiofrequency energy, is applied to the tissue with energy of about 10 J/cm2 to about 1000 J/cm2 is applied to the tissue. Preferably, about 50 J/cm2 to about 300 J/cm2 is applied to the tissue.
Free radical-mediated mechanisms of cellular damage are believed to be involved after periods of ischemia and reperfusion. Nishikawa, Ultrastructural Changes and Lipid Peroxidation in Rat Adipomusculocutaneous Flap Isotransplants after Normothermic Storage and Reperfusion, Transplantation, Vol. 54, 795-801, 1992. More particularly, it is known that fat has a greater predisposition to free radical damage than skin. Id; Coban, Ischemia-Reperfusion Injury of Adipofascial Tissue: An Experimental Study Evaluating Early Histologic and Biochemical Alterations in Rats, Mediators of Inflammation, Vol. 5, 304-308, 2005 (fat tissue is more susceptible to ischemic events). These studies look to minimize injury to fat tissue during transplants. By contrast, while not intending to be bound by theory, it is believed that it is beneficial to augment ischemia-reperfusion injury in the adipose tissue, thus enhancing adipose tissue necrosis.
The damage of reperfusion injury is due in part to the inflammatory response of damaged tissues. White blood cells carried to the area by the newly returning blood release a host of inflammatory factors such as interleukins as well as free radicals in response to tissue damage. The restored blood flow reintroduces oxygen within cells that damages cellular proteins, DNA, and the plasma membrane. Damage to the cell's membrane may in turn cause the release of more free radicals. Such reactive species may also act indirectly in redox signaling to turn on apoptosis. Redox signaling is the concept that free radicals, reactive oxygen species (ROS), and other electronically-activated species act as messengers in biological systems. Leukocytes may also build up in small capillaries, obstructing them and leading to more ischemia.
In certain embodiments, the methods of the invention further comprise treating the region to encourage formation of oxygen radicals. Oxygen radicals are damaging to tissues, and their concentration may be increased in a number of ways, including locally administering oxygen radical forming compounds (such as bleomycin) and compounds (such as the interleukins and other immune adjuvants) that stimulate inflammation by, for example, stimulating release of inflammatory mediators and/or leukocyte activity. In yet another embodiment, the method further comprises treating the region to encourage formation of intracellular and/or extracellular ion concentrations at other than normal levels.
The present invention provides methods of treating subcutaneous adipose tissue in a region of a subject's body, comprising exposing said region to a cooling element under conditions effective to cool said tissue; and stimulating reperfusion in the cooled tissue by exposing the tissue to an energy source to increase the blood flow rate to the cooled tissue. In one embodiment, stimulating reperfusion in the tissue causes ischemia-reperfusion injury to the tissue. Ischemia-reperfusion injury in the tissue permanently damages adipocytes present in the tissue.
In some embodiments, the methods further comprise determining the amount of adipocytes present in the tissue. The determination may be made before the exposing step, after the exposing step, or both before and after the exposing step.
In another embodiment, the present invention provides methods of treating subcutaneous adipose tissue in a region of a subject's body, comprising exposing said region to a cooling element under conditions effective to cool said tissue; and causing an ischemia-reperfusion injury to the cooled tissue by exposing the tissue to an energy source to increase the blood flow rate to the cooled tissue.
In the foregoing specification, the concepts have been described with reference to specific embodiments. Many aspects and embodiments have been described above and are merely exemplary and not limiting. After reading this specification, skilled artisans appreciate that other aspects and embodiments are possible without departing from the scope of the invention. Moreover, one of ordinary skill in the art appreciates that various modifications and changes can be made without departing from the scope of the invention as set forth in the claims below. Accordingly, the specification and figures are to be regarded in an illustrative rather than a restrictive sense, and all such modifications are intended to be included within the scope of invention.
Benefits, other advantages, and solutions to problems have been described above with regard to specific embodiments. However, the benefits, advantages, solutions to problems, and any feature(s) that may cause the same to occur or become more pronounced are not to be construed as a critical, required, or essential feature of any or all the claims.
It is to be appreciated that certain features are, for clarity, described herein in the context of separate embodiments, but may also be provided in combination in a single embodiment. Conversely, various features that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any subcombination. Further, reference to values stated in ranges include each and every value within that range.
This application is a continuation of U.S. patent application Ser. No. 13/471,826, filed May 15, 2012, which is a continuation of U.S. patent application Ser. No. 14/558,046, filed Nov. 9, 2006, now U.S. Pat. No. 8,192,474. Each of these applications is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
681806 | Mignault et al. | Sep 1901 | A |
889810 | Robinson et al. | Jun 1908 | A |
1093868 | Leighty | Apr 1914 | A |
2516491 | Swastek | Jul 1950 | A |
2521780 | Dodd et al. | Sep 1950 | A |
2726658 | Chessey | Dec 1955 | A |
2766619 | Tribus et al. | Oct 1956 | A |
2851602 | Cramwinckel et al. | Sep 1958 | A |
3093135 | Hirschhorn | Jun 1963 | A |
3132688 | Nowak | May 1964 | A |
3133539 | Eidus et al. | May 1964 | A |
3282267 | Eidus | Nov 1966 | A |
3341230 | Louis | Sep 1967 | A |
3502080 | Hirschhorn | Mar 1970 | A |
3566871 | Richter et al. | Mar 1971 | A |
3587577 | Zubkov et al. | Jun 1971 | A |
3591645 | Selwitz | Jul 1971 | A |
3692338 | Nick | Sep 1972 | A |
3703897 | Mack et al. | Nov 1972 | A |
3710784 | Taylor | Jan 1973 | A |
3786814 | Armao | Jan 1974 | A |
3827436 | Andera et al. | Aug 1974 | A |
3942519 | Shock | Mar 1976 | A |
3948269 | Zimmer | Apr 1976 | A |
3986385 | Johnston et al. | Oct 1976 | A |
3993053 | Grossan | Nov 1976 | A |
4002221 | Buchalter | Jan 1977 | A |
4008910 | Roche | Feb 1977 | A |
4026299 | Sauder | May 1977 | A |
4140130 | Storm | Feb 1979 | A |
4149529 | Copeland et al. | Apr 1979 | A |
4178429 | Scheffer | Dec 1979 | A |
4202336 | van Gerven | May 1980 | A |
4266043 | Fujii et al. | May 1981 | A |
4269068 | Molina | May 1981 | A |
4381009 | Del Bon | Apr 1983 | A |
4396011 | Mack et al. | Aug 1983 | A |
4459854 | Richardson et al. | Jul 1984 | A |
4470263 | Lehovec et al. | Sep 1984 | A |
4483341 | Les | Nov 1984 | A |
4528979 | Marchenko et al. | Jul 1985 | A |
4531524 | Mioduski | Jul 1985 | A |
4548212 | Leung | Oct 1985 | A |
4555313 | Duchane et al. | Nov 1985 | A |
4585002 | Kissin | Apr 1986 | A |
4603076 | Bowditch et al. | Jul 1986 | A |
4614191 | Perler et al. | Sep 1986 | A |
4644955 | Mioduski | Feb 1987 | A |
4664110 | Schanzlin | May 1987 | A |
4700701 | Montaldi | Oct 1987 | A |
4718429 | Smidt | Jan 1988 | A |
4741338 | Miyamae | May 1988 | A |
4758217 | Gueret | Jul 1988 | A |
4764463 | Mason et al. | Aug 1988 | A |
4802475 | Weshahy | Feb 1989 | A |
4832022 | Tjulkov et al. | May 1989 | A |
4846176 | Golden | Jul 1989 | A |
4850340 | Onishi | Jul 1989 | A |
4869250 | Bitterly | Sep 1989 | A |
4880564 | Abel et al. | Nov 1989 | A |
4905697 | Heggs et al. | Mar 1990 | A |
4906463 | Cleary et al. | Mar 1990 | A |
4930317 | Klein | Jun 1990 | A |
4935345 | Guilbeau et al. | Jun 1990 | A |
4961422 | Marchosky et al. | Oct 1990 | A |
4962761 | Golden | Oct 1990 | A |
4990144 | Blott et al. | Feb 1991 | A |
5007433 | Hermsdoerffer et al. | Apr 1991 | A |
5018521 | Campbell et al. | May 1991 | A |
5024650 | Hagiwara et al. | Jun 1991 | A |
5065752 | Sessions et al. | Nov 1991 | A |
5069208 | Noppel et al. | Dec 1991 | A |
5084671 | Miyata et al. | Jan 1992 | A |
5108390 | Potocky et al. | Apr 1992 | A |
5119674 | Nielsen | Jun 1992 | A |
5139496 | Hed et al. | Aug 1992 | A |
5143063 | Fellner | Sep 1992 | A |
5148804 | Hill et al. | Sep 1992 | A |
5158070 | Dory | Oct 1992 | A |
5160312 | Voelkel | Nov 1992 | A |
5169384 | Bosniak et al. | Dec 1992 | A |
5197466 | Marchosky et al. | Mar 1993 | A |
5207674 | Hamilton | May 1993 | A |
5209227 | Deutsch | May 1993 | A |
5221726 | Dabi et al. | Jun 1993 | A |
5264234 | Windhab et al. | Nov 1993 | A |
5277030 | Miller | Jan 1994 | A |
5314423 | Seney et al. | May 1994 | A |
5327886 | Chiu | Jul 1994 | A |
5330745 | Mcdow et al. | Jul 1994 | A |
5333460 | Lewis et al. | Aug 1994 | A |
5334131 | Omandam et al. | Aug 1994 | A |
5336616 | Livesey et al. | Aug 1994 | A |
5339541 | Owens | Aug 1994 | A |
5342617 | Gold et al. | Aug 1994 | A |
5351677 | Kami et al. | Oct 1994 | A |
5358467 | Milstein et al. | Oct 1994 | A |
5362966 | Rosenthal et al. | Nov 1994 | A |
5363347 | Nguyen | Nov 1994 | A |
5372608 | Johnson | Dec 1994 | A |
5386837 | Sterzer | Feb 1995 | A |
5411541 | Bell et al. | May 1995 | A |
5427772 | Hagan et al. | Jun 1995 | A |
5433717 | Rubinsky et al. | Jul 1995 | A |
5456703 | Beeuwkes, III et al. | Oct 1995 | A |
5472416 | Blugerman et al. | Dec 1995 | A |
5486207 | Mahawili | Jan 1996 | A |
5497596 | Zatkulak | Mar 1996 | A |
5501655 | Rolt et al. | Mar 1996 | A |
5505726 | Meserol | Apr 1996 | A |
5505730 | Edwards et al. | Apr 1996 | A |
5507790 | Weiss | Apr 1996 | A |
5514105 | Goodman, Jr. et al. | May 1996 | A |
5514170 | Mauch | May 1996 | A |
5516505 | Mcdow | May 1996 | A |
5531742 | Barken | Jul 1996 | A |
5558376 | Woehl | Sep 1996 | A |
5562604 | Yablon et al. | Oct 1996 | A |
5571801 | Segall et al. | Nov 1996 | A |
5575812 | Owens et al. | Nov 1996 | A |
5603221 | Maytal | Feb 1997 | A |
5628769 | Saringer | May 1997 | A |
5634890 | Morris | Jun 1997 | A |
5634940 | Panyard | Jun 1997 | A |
5647051 | Neer | Jul 1997 | A |
5647868 | Chinn | Jul 1997 | A |
5650450 | Lovette et al. | Jul 1997 | A |
5651773 | Perry et al. | Jul 1997 | A |
5654279 | Rubinsky et al. | Aug 1997 | A |
5654546 | Lindsay et al. | Aug 1997 | A |
5660836 | Knowlton et al. | Aug 1997 | A |
5665053 | Jacobs | Sep 1997 | A |
5672172 | Zupkas | Sep 1997 | A |
5700284 | Owens et al. | Dec 1997 | A |
5725483 | Podolsky | Mar 1998 | A |
5733280 | Avitall | Mar 1998 | A |
5741248 | Stern et al. | Apr 1998 | A |
5746702 | Gelfgat et al. | May 1998 | A |
5746736 | Tankovich | May 1998 | A |
5755663 | Larsen et al. | May 1998 | A |
5755753 | Knowlton et al. | May 1998 | A |
5755755 | Panyard | May 1998 | A |
5759182 | Varney et al. | Jun 1998 | A |
5759764 | Polovina et al. | Jun 1998 | A |
5769879 | Richards et al. | Jun 1998 | A |
5785955 | Fischer | Jul 1998 | A |
5792080 | Ookawa et al. | Aug 1998 | A |
5800490 | Patz et al. | Sep 1998 | A |
5802865 | Strauss | Sep 1998 | A |
5814040 | Nelson et al. | Sep 1998 | A |
5817050 | Klein et al. | Oct 1998 | A |
5817149 | Owens et al. | Oct 1998 | A |
5817150 | Owens et al. | Oct 1998 | A |
5830208 | Muller | Nov 1998 | A |
5833685 | Tortal et al. | Nov 1998 | A |
5844013 | Kenndoff et al. | Dec 1998 | A |
5853364 | Baker et al. | Dec 1998 | A |
5865841 | Kolen et al. | Feb 1999 | A |
5871524 | Knowlton | Feb 1999 | A |
5871526 | Gibbs et al. | Feb 1999 | A |
5885211 | Eppstein et al. | Mar 1999 | A |
5891617 | Watson et al. | Apr 1999 | A |
5895418 | Saringer | Apr 1999 | A |
5901707 | Goncalves | May 1999 | A |
5902256 | Benaron | May 1999 | A |
5919219 | Knowlton et al. | Jul 1999 | A |
5944748 | Mager et al. | Aug 1999 | A |
5948011 | Knowlton et al. | Sep 1999 | A |
5954680 | Augustine et al. | Sep 1999 | A |
5964092 | Tozuka et al. | Oct 1999 | A |
5964749 | Eckhouse et al. | Oct 1999 | A |
5967976 | Larsen et al. | Oct 1999 | A |
5980561 | Kolen et al. | Nov 1999 | A |
5986167 | Arteman et al. | Nov 1999 | A |
5989286 | Owens et al. | Nov 1999 | A |
5997530 | Nelson et al. | Dec 1999 | A |
6017337 | Pira | Jan 2000 | A |
6023932 | Johnston | Feb 2000 | A |
6032675 | Rubinsky | Mar 2000 | A |
6039694 | Larson et al. | Mar 2000 | A |
6041787 | Rubinsky | Mar 2000 | A |
6047215 | McClure et al. | Apr 2000 | A |
6049927 | Thomas et al. | Apr 2000 | A |
6051159 | Hao et al. | Apr 2000 | A |
6071239 | Cribbs et al. | Jun 2000 | A |
6074415 | Der Ovanesian | Jun 2000 | A |
6093230 | Johnson et al. | Jul 2000 | A |
6102885 | Bass | Aug 2000 | A |
6104952 | Tu et al. | Aug 2000 | A |
6104959 | Spertell et al. | Aug 2000 | A |
6106517 | Zupkas | Aug 2000 | A |
6113558 | Rosenschein et al. | Sep 2000 | A |
6113559 | Klopotek | Sep 2000 | A |
6113626 | Clifton et al. | Sep 2000 | A |
6120519 | Weber et al. | Sep 2000 | A |
6139544 | Mikus et al. | Oct 2000 | A |
6150148 | Nanda et al. | Nov 2000 | A |
6151735 | Koby et al. | Nov 2000 | A |
6152952 | Owens et al. | Nov 2000 | A |
6171301 | Nelson et al. | Jan 2001 | B1 |
6180867 | Hedengren et al. | Jan 2001 | B1 |
6226996 | Weber et al. | May 2001 | B1 |
6241753 | Knowlton | Jun 2001 | B1 |
6264649 | Whitcroft et al. | Jul 2001 | B1 |
6273884 | Altshuler et al. | Aug 2001 | B1 |
6290988 | Van Vilsteren et al. | Sep 2001 | B1 |
6311090 | Knowlton | Oct 2001 | B1 |
6311497 | Chung | Nov 2001 | B1 |
6312453 | Stefanile et al. | Nov 2001 | B1 |
6350276 | Knowlton | Feb 2002 | B1 |
6354297 | Eiseman | Mar 2002 | B1 |
6357907 | Cleveland et al. | Mar 2002 | B1 |
6375673 | Clifton et al. | Apr 2002 | B1 |
6377854 | Knowlton | Apr 2002 | B1 |
6377855 | Knowlton | Apr 2002 | B1 |
6381497 | Knowlton | Apr 2002 | B1 |
6381498 | Knowlton | Apr 2002 | B1 |
6387380 | Knowlton | May 2002 | B1 |
6401722 | Krag | Jun 2002 | B1 |
6405090 | Knowlton | Jun 2002 | B1 |
6413255 | Stern | Jul 2002 | B1 |
6425912 | Knowlton | Jul 2002 | B1 |
6426445 | Young et al. | Jul 2002 | B1 |
6430446 | Knowlton | Aug 2002 | B1 |
6430956 | Haas et al. | Aug 2002 | B1 |
6438424 | Knowlton | Aug 2002 | B1 |
6438954 | Goetz et al. | Aug 2002 | B1 |
6438964 | Giblin | Aug 2002 | B1 |
6453202 | Knowlton | Sep 2002 | B1 |
6458888 | Hood et al. | Oct 2002 | B1 |
6461378 | Knowlton | Oct 2002 | B1 |
6470216 | Knowlton | Oct 2002 | B1 |
6471693 | Carroll et al. | Oct 2002 | B1 |
6475211 | Chess et al. | Nov 2002 | B2 |
6478811 | Dobak, III et al. | Nov 2002 | B1 |
6494844 | Van Bladel et al. | Dec 2002 | B1 |
6497721 | Ginsburg et al. | Dec 2002 | B2 |
6508831 | Kushnir | Jan 2003 | B1 |
6514244 | Pope et al. | Feb 2003 | B2 |
6519964 | Bieberich | Feb 2003 | B2 |
6523354 | Tolbert | Feb 2003 | B1 |
6527765 | Kelman et al. | Mar 2003 | B2 |
6527798 | Ginsburg et al. | Mar 2003 | B2 |
6544248 | Bass | Apr 2003 | B1 |
6547811 | Becker et al. | Apr 2003 | B1 |
6548297 | Kuri-Harcuch et al. | Apr 2003 | B1 |
6551255 | Van Bladel et al. | Apr 2003 | B2 |
6551341 | Boylan et al. | Apr 2003 | B2 |
6551348 | Blalock et al. | Apr 2003 | B1 |
6551349 | Lasheras et al. | Apr 2003 | B2 |
6569189 | Augustine et al. | May 2003 | B1 |
6585652 | Lang et al. | Jul 2003 | B2 |
6592577 | Abboud et al. | Jul 2003 | B2 |
6605080 | Altshuler et al. | Aug 2003 | B1 |
6607498 | Eshel | Aug 2003 | B2 |
6620187 | Carson et al. | Sep 2003 | B2 |
6620188 | Ginsburg et al. | Sep 2003 | B1 |
6620189 | Machold et al. | Sep 2003 | B1 |
6623430 | Slayton et al. | Sep 2003 | B1 |
6626854 | Friedman et al. | Sep 2003 | B2 |
6632219 | Baranov et al. | Oct 2003 | B1 |
6635053 | Lalonde et al. | Oct 2003 | B1 |
6643535 | Damasco et al. | Nov 2003 | B2 |
6645162 | Friedman et al. | Nov 2003 | B2 |
6645229 | Matsumura et al. | Nov 2003 | B2 |
6645232 | Carson | Nov 2003 | B2 |
6648904 | Altshuler et al. | Nov 2003 | B2 |
6656208 | Grahn et al. | Dec 2003 | B2 |
6660027 | Gruszecki et al. | Dec 2003 | B2 |
6662054 | Kreindel et al. | Dec 2003 | B2 |
6682550 | Clifton et al. | Jan 2004 | B2 |
6685731 | Kushnir et al. | Feb 2004 | B2 |
6694170 | Mikus et al. | Feb 2004 | B1 |
6695874 | Machold et al. | Feb 2004 | B2 |
6697670 | Chornenky | Feb 2004 | B2 |
6699237 | Weber et al. | Mar 2004 | B2 |
6699266 | Lachenbruch et al. | Mar 2004 | B2 |
6699267 | Voorhees et al. | Mar 2004 | B2 |
6718785 | Bieberich | Apr 2004 | B2 |
6741895 | Gafni et al. | May 2004 | B1 |
6743222 | Durkin et al. | Jun 2004 | B2 |
6746474 | Saadat | Jun 2004 | B2 |
6749624 | Knowlton | Jun 2004 | B2 |
6753182 | Kadkade et al. | Jun 2004 | B1 |
6764493 | Weber et al. | Jul 2004 | B1 |
6764502 | Bieberich | Jul 2004 | B2 |
6789545 | Littrup et al. | Sep 2004 | B2 |
6795728 | Chornenky et al. | Sep 2004 | B2 |
6820961 | Johnson | Nov 2004 | B2 |
6821274 | McHale et al. | Nov 2004 | B2 |
6840955 | Ein | Jan 2005 | B2 |
6849075 | Bertolero et al. | Feb 2005 | B2 |
6878144 | Altshuler et al. | Apr 2005 | B2 |
6889090 | Kreindel | May 2005 | B2 |
6892099 | Jaafar et al. | May 2005 | B2 |
6904956 | Noel | Jun 2005 | B2 |
6918903 | Bass | Jul 2005 | B2 |
6927316 | Fades, Jr. et al. | Aug 2005 | B1 |
6942022 | Blangetti et al. | Sep 2005 | B2 |
6945942 | Van Bladel et al. | Sep 2005 | B2 |
6948903 | Ablabutyan et al. | Sep 2005 | B2 |
6969399 | Schock et al. | Nov 2005 | B2 |
7005558 | Johansson et al. | Feb 2006 | B1 |
7006874 | Knowlton et al. | Feb 2006 | B2 |
7022121 | Stern et al. | Apr 2006 | B2 |
7037326 | Lee | May 2006 | B2 |
7054685 | Dimmer et al. | May 2006 | B2 |
7060061 | Altshuler et al. | Jun 2006 | B2 |
7077858 | Fletcher et al. | Jul 2006 | B2 |
7081111 | Svaasand et al. | Jul 2006 | B2 |
7083612 | Littrup et al. | Aug 2006 | B2 |
7096204 | Chen et al. | Aug 2006 | B1 |
7112712 | Ancell | Sep 2006 | B1 |
7115123 | Knowlton et al. | Oct 2006 | B2 |
7141049 | Stern et al. | Nov 2006 | B2 |
7183360 | Daniel et al. | Feb 2007 | B2 |
7189252 | Krueger | Mar 2007 | B2 |
7192426 | Baust et al. | Mar 2007 | B2 |
7204832 | Altshuler et al. | Apr 2007 | B2 |
7220778 | Anderson et al. | May 2007 | B2 |
7229436 | Stern et al. | Jun 2007 | B2 |
7258674 | Cribbs et al. | Aug 2007 | B2 |
7267675 | Stern et al. | Sep 2007 | B2 |
7276058 | Altshuler et al. | Oct 2007 | B2 |
7318821 | Lalonde et al. | Jan 2008 | B2 |
7331951 | Eshel et al. | Feb 2008 | B2 |
7347855 | Eshel et al. | Mar 2008 | B2 |
7367341 | Anderson et al. | May 2008 | B2 |
7532201 | Quistgaard et al. | May 2009 | B2 |
7572268 | Babaev | Aug 2009 | B2 |
7604632 | Howlett et al. | Oct 2009 | B2 |
7613523 | Eggers et al. | Nov 2009 | B2 |
7615016 | Barthe et al. | Nov 2009 | B2 |
7713266 | Elkins et al. | May 2010 | B2 |
7780656 | Tankovich | Aug 2010 | B2 |
7799018 | Goulko | Sep 2010 | B2 |
7824437 | Saunders | Nov 2010 | B1 |
7828831 | Tanhehco et al. | Nov 2010 | B1 |
7850683 | Elkins et al. | Dec 2010 | B2 |
7854754 | Ting et al. | Dec 2010 | B2 |
7862558 | Elkins et al. | Jan 2011 | B2 |
RE42277 | Jaafar et al. | Apr 2011 | E |
7938824 | Chornenky et al. | May 2011 | B2 |
7959657 | Harsy et al. | Jun 2011 | B1 |
7963959 | Da Silva et al. | Jun 2011 | B2 |
7967763 | Deem et al. | Jun 2011 | B2 |
7993330 | Goulko | Aug 2011 | B2 |
7998137 | Elkins et al. | Aug 2011 | B2 |
RE42835 | Chornenky et al. | Oct 2011 | E |
RE43009 | Chornenky et al. | Dec 2011 | E |
8133180 | Slayton et al. | Mar 2012 | B2 |
8133191 | Rosenberg et al. | Mar 2012 | B2 |
8192474 | Levinson | Jun 2012 | B2 |
8246611 | Paithankar et al. | Aug 2012 | B2 |
8275442 | Allison | Sep 2012 | B2 |
8285390 | Levinson et al. | Oct 2012 | B2 |
8333700 | Barthe et al. | Dec 2012 | B1 |
8337539 | Ting et al. | Dec 2012 | B2 |
8366622 | Slayton et al. | Feb 2013 | B2 |
8372130 | Young et al. | Feb 2013 | B2 |
8397518 | Vistakula et al. | Mar 2013 | B1 |
8414631 | Quisenberry et al. | Apr 2013 | B2 |
8433400 | Prushinskaya et al. | Apr 2013 | B2 |
8506486 | Slayton et al. | Aug 2013 | B2 |
8523775 | Barthe et al. | Sep 2013 | B2 |
8523791 | Castel | Sep 2013 | B2 |
8523927 | Levinson et al. | Sep 2013 | B2 |
8535228 | Slayton et al. | Sep 2013 | B2 |
8603073 | Allison | Dec 2013 | B2 |
8636665 | Slayton et al. | Jan 2014 | B2 |
8641622 | Barthe et al. | Feb 2014 | B2 |
8663112 | Slayton et al. | Mar 2014 | B2 |
8672848 | Slayton et al. | Mar 2014 | B2 |
8676332 | Fahey | Mar 2014 | B2 |
8690778 | Slayton et al. | Apr 2014 | B2 |
8690779 | Slayton et al. | Apr 2014 | B2 |
8690780 | Slayton et al. | Apr 2014 | B2 |
8702774 | Baker et al. | Apr 2014 | B2 |
8758215 | Legendre et al. | Jun 2014 | B2 |
8764693 | Graham et al. | Jul 2014 | B1 |
8834547 | Anderson et al. | Sep 2014 | B2 |
9149322 | Knowlton | Oct 2015 | B2 |
20010005791 | Ginsburg et al. | Jun 2001 | A1 |
20010007952 | Shimizu | Jul 2001 | A1 |
20010023364 | Ahn | Sep 2001 | A1 |
20010031459 | Fahy et al. | Oct 2001 | A1 |
20010039439 | Elkins et al. | Nov 2001 | A1 |
20010045104 | Bailey, Sr. et al. | Nov 2001 | A1 |
20010047196 | Ginsburg et al. | Nov 2001 | A1 |
20020026226 | Ein | Feb 2002 | A1 |
20020032473 | Kushnir et al. | Mar 2002 | A1 |
20020042607 | Palmer et al. | Apr 2002 | A1 |
20020049483 | Knowlton | Apr 2002 | A1 |
20020058975 | Bieberich | May 2002 | A1 |
20020062142 | Knowlton | May 2002 | A1 |
20020068338 | Nanda et al. | Jun 2002 | A1 |
20020068874 | Zuckerwar et al. | Jun 2002 | A1 |
20020082668 | Man | Jun 2002 | A1 |
20020103520 | Latham | Aug 2002 | A1 |
20020107558 | Clifton et al. | Aug 2002 | A1 |
20020117293 | Campbell | Aug 2002 | A1 |
20020120315 | Furuno et al. | Aug 2002 | A1 |
20020128648 | Weber et al. | Sep 2002 | A1 |
20020151830 | Kahn | Oct 2002 | A1 |
20020151887 | Stern et al. | Oct 2002 | A1 |
20020156509 | Cheung | Oct 2002 | A1 |
20020188286 | Quijano et al. | Dec 2002 | A1 |
20020198518 | Mikus et al. | Dec 2002 | A1 |
20030032900 | Ella | Feb 2003 | A1 |
20030044764 | Soane et al. | Mar 2003 | A1 |
20030055414 | Altshuler et al. | Mar 2003 | A1 |
20030062040 | Lurie et al. | Apr 2003 | A1 |
20030069618 | Smith, III et al. | Apr 2003 | A1 |
20030077326 | Newton et al. | Apr 2003 | A1 |
20030077329 | Kipp et al. | Apr 2003 | A1 |
20030079488 | Bieberich | May 2003 | A1 |
20030100936 | Altshuler et al. | May 2003 | A1 |
20030109908 | Lachenbruch et al. | Jun 2003 | A1 |
20030109910 | Lachenbruch et al. | Jun 2003 | A1 |
20030109911 | Lachenbruch et al. | Jun 2003 | A1 |
20030109912 | Joye et al. | Jun 2003 | A1 |
20030114885 | Nova et al. | Jun 2003 | A1 |
20030120268 | Bertolero et al. | Jun 2003 | A1 |
20030125649 | McIntosh et al. | Jul 2003 | A1 |
20030187488 | Kreindel et al. | Oct 2003 | A1 |
20030199226 | Sommer et al. | Oct 2003 | A1 |
20030199859 | Altshuler et al. | Oct 2003 | A1 |
20030220594 | Halvorson et al. | Nov 2003 | A1 |
20030220635 | Knowlton et al. | Nov 2003 | A1 |
20030220674 | Anderson et al. | Nov 2003 | A1 |
20030236487 | Knowlton | Dec 2003 | A1 |
20040002705 | Knowlton et al. | Jan 2004 | A1 |
20040006328 | Anderson | Jan 2004 | A1 |
20040009936 | Tang et al. | Jan 2004 | A1 |
20040024437 | Machold et al. | Feb 2004 | A1 |
20040030332 | Knowlton et al. | Feb 2004 | A1 |
20040034341 | Altshuler et al. | Feb 2004 | A1 |
20040039312 | Hillstead | Feb 2004 | A1 |
20040044384 | Leber et al. | Mar 2004 | A1 |
20040049178 | Abboud et al. | Mar 2004 | A1 |
20040073079 | Altshuler et al. | Apr 2004 | A1 |
20040074629 | Noel | Apr 2004 | A1 |
20040077977 | Ella et al. | Apr 2004 | A1 |
20040082886 | Timpson | Apr 2004 | A1 |
20040093042 | Altshuler et al. | May 2004 | A1 |
20040104012 | Zhou et al. | Jun 2004 | A1 |
20040106867 | Eshel et al. | Jun 2004 | A1 |
20040133251 | Altshuler et al. | Jul 2004 | A1 |
20040162596 | Altshuler et al. | Aug 2004 | A1 |
20040176667 | Mihai et al. | Sep 2004 | A1 |
20040186535 | Knowlton | Sep 2004 | A1 |
20040199226 | Shadduck | Oct 2004 | A1 |
20040206365 | Knowlton | Oct 2004 | A1 |
20040210214 | Knowlton | Oct 2004 | A1 |
20040210287 | Greene | Oct 2004 | A1 |
20040215294 | Littrup et al. | Oct 2004 | A1 |
20040249427 | Nabilsi et al. | Dec 2004 | A1 |
20040259855 | Anderson et al. | Dec 2004 | A1 |
20040260209 | Ella et al. | Dec 2004 | A1 |
20040260210 | Ella et al. | Dec 2004 | A1 |
20040260211 | Maalouf | Dec 2004 | A1 |
20040267339 | Yon et al. | Dec 2004 | A1 |
20050010197 | Lau et al. | Jan 2005 | A1 |
20050033957 | Enokida | Feb 2005 | A1 |
20050049526 | Baer | Mar 2005 | A1 |
20050049543 | Anderson et al. | Mar 2005 | A1 |
20050049661 | Koffroth | Mar 2005 | A1 |
20050113725 | Masuda | May 2005 | A1 |
20050143781 | Carbunaru et al. | Jun 2005 | A1 |
20050145372 | Noel | Jul 2005 | A1 |
20050149153 | Nakase et al. | Jul 2005 | A1 |
20050154314 | Quistgaard | Jul 2005 | A1 |
20050154431 | Quistgaard et al. | Jul 2005 | A1 |
20050159986 | Breeland et al. | Jul 2005 | A1 |
20050177075 | Meunier et al. | Aug 2005 | A1 |
20050182462 | Chornenky et al. | Aug 2005 | A1 |
20050187495 | Quistgaard et al. | Aug 2005 | A1 |
20050187597 | Vanderschuit | Aug 2005 | A1 |
20050203446 | Takashima | Sep 2005 | A1 |
20050215987 | Slatkine | Sep 2005 | A1 |
20050222565 | Manstein | Oct 2005 | A1 |
20050251117 | Anderson et al. | Nov 2005 | A1 |
20050251120 | Anderson et al. | Nov 2005 | A1 |
20050261753 | Littrup et al. | Nov 2005 | A1 |
20050277859 | Carlsmith et al. | Dec 2005 | A1 |
20050283144 | Shiono et al. | Dec 2005 | A1 |
20060030778 | Mendlein et al. | Feb 2006 | A1 |
20060035380 | Saint-Leger | Feb 2006 | A1 |
20060036300 | Kreindel | Feb 2006 | A1 |
20060041704 | Choi | Feb 2006 | A1 |
20060074313 | Slayton et al. | Apr 2006 | A1 |
20060079852 | Bubb et al. | Apr 2006 | A1 |
20060094988 | Tosaya et al. | May 2006 | A1 |
20060106836 | Masugi et al. | May 2006 | A1 |
20060111613 | Boutillette et al. | May 2006 | A1 |
20060122509 | Desilets | Jun 2006 | A1 |
20060189964 | Anderson et al. | Aug 2006 | A1 |
20060195168 | Dunbar et al. | Aug 2006 | A1 |
20060200063 | Munro et al. | Sep 2006 | A1 |
20060206040 | Greenberg et al. | Sep 2006 | A1 |
20060206110 | Knowlton et al. | Sep 2006 | A1 |
20060234899 | Nekmard et al. | Oct 2006 | A1 |
20060259102 | Slatkine | Nov 2006 | A1 |
20060265032 | Hennings et al. | Nov 2006 | A1 |
20060270745 | Hunt et al. | Nov 2006 | A1 |
20060293734 | Scott et al. | Dec 2006 | A1 |
20070010811 | Stern et al. | Jan 2007 | A1 |
20070010861 | Anderson et al. | Jan 2007 | A1 |
20070032561 | Lin et al. | Feb 2007 | A1 |
20070038156 | Rosenberg | Feb 2007 | A1 |
20070055156 | Desilets et al. | Mar 2007 | A1 |
20070055173 | DeLonzor et al. | Mar 2007 | A1 |
20070055179 | Deem et al. | Mar 2007 | A1 |
20070055180 | Deem et al. | Mar 2007 | A1 |
20070055181 | Deem et al. | Mar 2007 | A1 |
20070073367 | Jones et al. | Mar 2007 | A1 |
20070078502 | Weber et al. | Apr 2007 | A1 |
20070100398 | Sloan | May 2007 | A1 |
20070106342 | Schumann | May 2007 | A1 |
20070129714 | Elkins | Jun 2007 | A1 |
20070135876 | Weber | Jun 2007 | A1 |
20070141265 | Thomson | Jun 2007 | A1 |
20070179482 | Anderson et al. | Aug 2007 | A1 |
20070198071 | Ting et al. | Aug 2007 | A1 |
20070219540 | Masotti et al. | Sep 2007 | A1 |
20070239062 | Chopra | Oct 2007 | A1 |
20070239075 | Rosenberg et al. | Oct 2007 | A1 |
20070239150 | Zvuloni et al. | Oct 2007 | A1 |
20070249519 | Guha et al. | Oct 2007 | A1 |
20070255187 | Branch | Nov 2007 | A1 |
20070255274 | Stern et al. | Nov 2007 | A1 |
20070255362 | Levinson et al. | Nov 2007 | A1 |
20070265585 | Joshi et al. | Nov 2007 | A1 |
20070265614 | Stern et al. | Nov 2007 | A1 |
20070270925 | Levinson | Nov 2007 | A1 |
20070282249 | Quisenberry et al. | Dec 2007 | A1 |
20070282318 | Spooner et al. | Dec 2007 | A1 |
20080014627 | Merchant et al. | Jan 2008 | A1 |
20080046047 | Jacobs | Feb 2008 | A1 |
20080058784 | Manstein et al. | Mar 2008 | A1 |
20080077201 | Levinson et al. | Mar 2008 | A1 |
20080077202 | Levinson | Mar 2008 | A1 |
20080077211 | Levinson et al. | Mar 2008 | A1 |
20080097207 | Cai et al. | Apr 2008 | A1 |
20080139901 | Altshuler et al. | Jun 2008 | A1 |
20080140061 | Toubia et al. | Jun 2008 | A1 |
20080140371 | Warner | Jun 2008 | A1 |
20080161892 | Mercuro et al. | Jul 2008 | A1 |
20080183164 | Elkins et al. | Jul 2008 | A1 |
20080188915 | Mills et al. | Aug 2008 | A1 |
20080248554 | Merchant et al. | Oct 2008 | A1 |
20080269851 | Deem et al. | Oct 2008 | A1 |
20080287839 | Rosen et al. | Nov 2008 | A1 |
20080300529 | Reinstein | Dec 2008 | A1 |
20080312651 | Pope et al. | Dec 2008 | A1 |
20090012434 | Anderson | Jan 2009 | A1 |
20090018623 | Levinson et al. | Jan 2009 | A1 |
20090018624 | Levinson et al. | Jan 2009 | A1 |
20090018625 | Levinson et al. | Jan 2009 | A1 |
20090018626 | Levinson et al. | Jan 2009 | A1 |
20090018627 | Levinson et al. | Jan 2009 | A1 |
20090024023 | Welches et al. | Jan 2009 | A1 |
20090076488 | Welches et al. | Mar 2009 | A1 |
20090112134 | Avni | Apr 2009 | A1 |
20090118722 | Ebbers et al. | May 2009 | A1 |
20090149929 | Levinson et al. | Jun 2009 | A1 |
20090149930 | Schenck | Jun 2009 | A1 |
20090171253 | Davenport | Jul 2009 | A1 |
20090171334 | Elkins et al. | Jul 2009 | A1 |
20090221938 | Rosenberg et al. | Sep 2009 | A1 |
20090226424 | Hsu | Sep 2009 | A1 |
20090276018 | Brader | Nov 2009 | A1 |
20090281464 | Cioanta et al. | Nov 2009 | A1 |
20090299234 | Cho et al. | Dec 2009 | A1 |
20090306749 | Mulindwa | Dec 2009 | A1 |
20090312676 | Rousso et al. | Dec 2009 | A1 |
20090312693 | Thapliyal et al. | Dec 2009 | A1 |
20090326621 | El-Galley | Dec 2009 | A1 |
20100015190 | Hassler | Jan 2010 | A1 |
20100028969 | Mueller et al. | Feb 2010 | A1 |
20100030306 | Edelman et al. | Feb 2010 | A1 |
20100036295 | Altshuler et al. | Feb 2010 | A1 |
20100042087 | Goldboss et al. | Feb 2010 | A1 |
20100049178 | Deem et al. | Feb 2010 | A1 |
20100081971 | Allison | Apr 2010 | A1 |
20100087806 | Da Silva et al. | Apr 2010 | A1 |
20100152824 | Allison | Jun 2010 | A1 |
20100168726 | Brookman | Jul 2010 | A1 |
20100179531 | Nebrigic et al. | Jul 2010 | A1 |
20100198064 | Perl et al. | Aug 2010 | A1 |
20100217349 | Fahey et al. | Aug 2010 | A1 |
20100241023 | Gilbert | Sep 2010 | A1 |
20100268220 | Johnson et al. | Oct 2010 | A1 |
20100280582 | Baker et al. | Nov 2010 | A1 |
20110009860 | Chornenky et al. | Jan 2011 | A1 |
20110040235 | Castel | Feb 2011 | A1 |
20110040299 | Kim et al. | Feb 2011 | A1 |
20110046523 | Altshuler et al. | Feb 2011 | A1 |
20110060323 | Baust et al. | Mar 2011 | A1 |
20110066083 | Tosaya et al. | Mar 2011 | A1 |
20110066216 | Ting et al. | Mar 2011 | A1 |
20110077557 | Wing et al. | Mar 2011 | A1 |
20110077723 | Parish et al. | Mar 2011 | A1 |
20110112405 | Barthe et al. | May 2011 | A1 |
20110112520 | Kreindel | May 2011 | A1 |
20110144631 | Elkins et al. | Jun 2011 | A1 |
20110152849 | Baust et al. | Jun 2011 | A1 |
20110172651 | Altshuler et al. | Jul 2011 | A1 |
20110189129 | Qiu et al. | Aug 2011 | A1 |
20110196395 | Maschke | Aug 2011 | A1 |
20110196438 | Winozil et al. | Aug 2011 | A1 |
20110202048 | Nebrigic et al. | Aug 2011 | A1 |
20110238050 | Allison et al. | Sep 2011 | A1 |
20110238051 | Levinson et al. | Sep 2011 | A1 |
20110257642 | Griggs, III | Oct 2011 | A1 |
20110288537 | Halaka | Nov 2011 | A1 |
20110300079 | Martens et al. | Dec 2011 | A1 |
20110301585 | Goulko | Dec 2011 | A1 |
20110313411 | Anderson et al. | Dec 2011 | A1 |
20110313412 | Kim et al. | Dec 2011 | A1 |
20120010609 | Deem et al. | Jan 2012 | A1 |
20120016239 | Barthe et al. | Jan 2012 | A1 |
20120022518 | Levinson | Jan 2012 | A1 |
20120022622 | Johnson et al. | Jan 2012 | A1 |
20120035475 | Barthe et al. | Feb 2012 | A1 |
20120035476 | Barthe et al. | Feb 2012 | A1 |
20120041525 | Kami | Feb 2012 | A1 |
20120046547 | Barthe et al. | Feb 2012 | A1 |
20120053458 | Barthe et al. | Mar 2012 | A1 |
20120065629 | Elkins et al. | Mar 2012 | A1 |
20120083862 | Altshuler et al. | Apr 2012 | A1 |
20120101549 | Schumann | Apr 2012 | A1 |
20120109041 | Munz | May 2012 | A1 |
20120158100 | Schomacker | Jun 2012 | A1 |
20120209363 | Williams, III et al. | Aug 2012 | A1 |
20120233736 | Tepper et al. | Sep 2012 | A1 |
20120239123 | Weber et al. | Sep 2012 | A1 |
20120253416 | Erez et al. | Oct 2012 | A1 |
20120259322 | Fourkas et al. | Oct 2012 | A1 |
20120277674 | Clark, III et al. | Nov 2012 | A1 |
20120310232 | Erez | Dec 2012 | A1 |
20130018236 | Altshuler et al. | Jan 2013 | A1 |
20130019374 | Schwartz | Jan 2013 | A1 |
20130035680 | Ben-Haim et al. | Feb 2013 | A1 |
20130066309 | Levinson | Mar 2013 | A1 |
20130073017 | Liu et al. | Mar 2013 | A1 |
20130079684 | Rosen et al. | Mar 2013 | A1 |
20130116758 | Levinson et al. | May 2013 | A1 |
20130116759 | Levinson et al. | May 2013 | A1 |
20130150844 | Deem et al. | Jun 2013 | A1 |
20130158440 | Allison | Jun 2013 | A1 |
20130158636 | Ting et al. | Jun 2013 | A1 |
20130166003 | Johnson et al. | Jun 2013 | A1 |
20130190744 | Avram et al. | Jul 2013 | A1 |
20130238062 | Ron Edoute et al. | Sep 2013 | A1 |
20130245507 | Khorassani Zadeh | Sep 2013 | A1 |
20130253384 | Anderson et al. | Sep 2013 | A1 |
20130253493 | Anderson et al. | Sep 2013 | A1 |
20130253494 | Anderson et al. | Sep 2013 | A1 |
20130253495 | Anderson et al. | Sep 2013 | A1 |
20130253496 | Anderson et al. | Sep 2013 | A1 |
20130303904 | Barthe et al. | Nov 2013 | A1 |
20130303905 | Barthe et al. | Nov 2013 | A1 |
20130331914 | Lee et al. | Dec 2013 | A1 |
20140005759 | Fahey et al. | Jan 2014 | A1 |
20140005760 | Levinson et al. | Jan 2014 | A1 |
20140067025 | Levinson et al. | Mar 2014 | A1 |
20140142469 | Britva et al. | May 2014 | A1 |
20140200487 | Ramdas et al. | Jul 2014 | A1 |
20140200488 | Seo et al. | Jul 2014 | A1 |
20140222121 | Spence et al. | Aug 2014 | A1 |
20140277219 | Nanda | Sep 2014 | A1 |
20140277302 | Weber et al. | Sep 2014 | A1 |
20140277303 | Biser et al. | Sep 2014 | A1 |
20140303697 | Anderson et al. | Oct 2014 | A1 |
20150141797 | Turnquist | May 2015 | A1 |
20150209174 | Abreu | Jul 2015 | A1 |
20150216719 | DeBenedictis et al. | Aug 2015 | A1 |
20150216720 | DeBenedictis et al. | Aug 2015 | A1 |
20150216816 | O'Neil et al. | Aug 2015 | A1 |
20150223975 | Anderson et al. | Aug 2015 | A1 |
20150283022 | Lee et al. | Oct 2015 | A1 |
20150328077 | Levinson | Nov 2015 | A1 |
20150335468 | Rose et al. | Nov 2015 | A1 |
20150342780 | Levinson et al. | Dec 2015 | A1 |
20160051308 | Pennybacker et al. | Feb 2016 | A1 |
20160051401 | Yee et al. | Feb 2016 | A1 |
20160135985 | Anderson | May 2016 | A1 |
20160220849 | Knowlton | Aug 2016 | A1 |
20170007309 | DeBenedictis et al. | Jan 2017 | A1 |
20170165105 | Anderson et al. | Jun 2017 | A1 |
20170196731 | DeBenedictis et al. | Jul 2017 | A1 |
20170239079 | Root et al. | Aug 2017 | A1 |
20170325992 | DeBenedictis et al. | Nov 2017 | A1 |
20170325993 | Jimenez Lozano et al. | Nov 2017 | A1 |
20170326042 | Zeng et al. | Nov 2017 | A1 |
20170326346 | Jimenez Lozano et al. | Nov 2017 | A1 |
20180185081 | O'Neil et al. | Jul 2018 | A1 |
20180185189 | Weber et al. | Jul 2018 | A1 |
20180263677 | Hilton et al. | Sep 2018 | A1 |
20180271767 | Jimenez Lozano et al. | Sep 2018 | A1 |
20180310950 | Yee et al. | Nov 2018 | A1 |
20190125424 | DeBenedictis et al. | May 2019 | A1 |
20190142493 | Debenedictis et al. | May 2019 | A1 |
Number | Date | Country |
---|---|---|
2011253768 | Jun 2012 | AU |
2441489 | Mar 2005 | CA |
2585214 | Oct 2007 | CA |
333982 | Nov 1958 | CH |
86200604 | Oct 1987 | CN |
2514795 | Oct 2002 | CN |
2514811 | Oct 2002 | CN |
1511503 | Jul 2004 | CN |
1741777 | Mar 2006 | CN |
1817990 | Aug 2006 | CN |
2843367 | Dec 2006 | CN |
2850584 | Dec 2006 | CN |
2850585 | Dec 2006 | CN |
200970265 | Nov 2007 | CN |
101259329 | Sep 2008 | CN |
101309657 | Nov 2008 | CN |
532976 | Sep 1931 | DE |
2851602 | Jun 1980 | DE |
4213584 | Nov 1992 | DE |
4224595 | Jan 1994 | DE |
4238291 | May 1994 | DE |
4445627 | Jun 1996 | DE |
19800416 | Jul 1999 | DE |
263069 | Apr 1988 | EP |
0397043 | Nov 1990 | EP |
0406244 | Jan 1991 | EP |
560309 | Sep 1993 | EP |
0598824 | Jun 1994 | EP |
1030611 | Aug 2000 | EP |
1201266 | May 2002 | EP |
1568395 | Aug 2005 | EP |
2260801 | Dec 2010 | EP |
2289598 | Mar 2011 | EP |
2527005 | Nov 2012 | EP |
854937 | Apr 1940 | FR |
2744358 | Aug 1997 | FR |
2745935 | Sep 1997 | FR |
2767476 | Feb 1999 | FR |
2776920 | Oct 1999 | FR |
2789893 | Aug 2000 | FR |
2805989 | Sep 2001 | FR |
387960 | Feb 1933 | GB |
2120944 | Dec 1983 | GB |
2202447 | Sep 1988 | GB |
2248183 | Apr 1992 | GB |
2263872 | Aug 1993 | GB |
2286660 | Aug 1995 | GB |
2323659 | Sep 1998 | GB |
58187454 | Nov 1983 | JP |
S6094113 | Jun 1985 | JP |
62082977 | Apr 1987 | JP |
63076895 | Apr 1988 | JP |
01223961 | Sep 1989 | JP |
03051964 | Mar 1991 | JP |
03259975 | Nov 1991 | JP |
04093597 | Mar 1992 | JP |
06261933 | Sep 1994 | JP |
07194666 | Aug 1995 | JP |
07268274 | Oct 1995 | JP |
09164163 | Jun 1997 | JP |
10216169 | Aug 1998 | JP |
10223961 | Aug 1998 | JP |
2000503154 | Mar 2000 | JP |
3065657 | Jul 2000 | JP |
2001046416 | Feb 2001 | JP |
2002125993 | May 2002 | JP |
2002224051 | Aug 2002 | JP |
2002282295 | Oct 2002 | JP |
2002290397 | Oct 2002 | JP |
2002543668 | Dec 2002 | JP |
2003190201 | Jul 2003 | JP |
2004013600 | Jan 2004 | JP |
2004073812 | Mar 2004 | JP |
2004159666 | Jun 2004 | JP |
2005039790 | Feb 2005 | JP |
2005065984 | Mar 2005 | JP |
2005110755 | Apr 2005 | JP |
2005509977 | Apr 2005 | JP |
3655820 | Jun 2005 | JP |
2005520608 | Jul 2005 | JP |
2005237908 | Sep 2005 | JP |
2005323716 | Nov 2005 | JP |
2006026001 | Feb 2006 | JP |
2006130055 | May 2006 | JP |
2006520949 | Sep 2006 | JP |
2007270459 | Oct 2007 | JP |
2008532591 | Aug 2008 | JP |
2009515232 | Apr 2009 | JP |
2009189757 | Aug 2009 | JP |
200173222 | Dec 1999 | KR |
1020040094508 | Nov 2004 | KR |
20090000258 | Jan 2009 | KR |
1020130043299 | Apr 2013 | KR |
1020140038165 | Mar 2014 | KR |
2036667 | Jun 1995 | RU |
532976 | Nov 1978 | SU |
0476644 | Feb 2002 | TW |
8503216 | Aug 1985 | WO |
9114417 | Oct 1991 | WO |
9300807 | Jan 1993 | WO |
9404116 | Mar 1994 | WO |
9623447 | Aug 1996 | WO |
9626693 | Sep 1996 | WO |
9636293 | Nov 1996 | WO |
9637158 | Nov 1996 | WO |
9704832 | Feb 1997 | WO |
9705828 | Feb 1997 | WO |
9722262 | Jun 1997 | WO |
9724088 | Jul 1997 | WO |
9725798 | Jul 1997 | WO |
9748440 | Dec 1997 | WO |
9829134 | Jul 1998 | WO |
9831321 | Jul 1998 | WO |
9841156 | Sep 1998 | WO |
9841157 | Sep 1998 | WO |
9909928 | Mar 1999 | WO |
9916502 | Apr 1999 | WO |
9938469 | Aug 1999 | WO |
9949937 | Oct 1999 | WO |
0044346 | Aug 2000 | WO |
0044349 | Aug 2000 | WO |
0065770 | Nov 2000 | WO |
0067685 | Nov 2000 | WO |
0100269 | Jan 2001 | WO |
0113989 | Mar 2001 | WO |
0114012 | Mar 2001 | WO |
0134048 | May 2001 | WO |
0205736 | Jan 2002 | WO |
02102921 | Dec 2002 | WO |
03007859 | Jan 2003 | WO |
03078596 | Sep 2003 | WO |
03079916 | Oct 2003 | WO |
2004000098 | Dec 2003 | WO |
2004080279 | Sep 2004 | WO |
2004090939 | Oct 2004 | WO |
2005033957 | Apr 2005 | WO |
2005046540 | May 2005 | WO |
2005060354 | Jul 2005 | WO |
2005096979 | Oct 2005 | WO |
2005112815 | Dec 2005 | WO |
2006066226 | Jun 2006 | WO |
2006094348 | Sep 2006 | WO |
2006106836 | Oct 2006 | WO |
2006116603 | Nov 2006 | WO |
2006127467 | Nov 2006 | WO |
2007012083 | Jan 2007 | WO |
2007028975 | Mar 2007 | WO |
2007041642 | Apr 2007 | WO |
2007101039 | Sep 2007 | WO |
2007127924 | Nov 2007 | WO |
2007145421 | Dec 2007 | WO |
2007145422 | Dec 2007 | WO |
2008006018 | Jan 2008 | WO |
2008039556 | Apr 2008 | WO |
2008039557 | Apr 2008 | WO |
2008055243 | May 2008 | WO |
2008143678 | Nov 2008 | WO |
2009011708 | Jan 2009 | WO |
2009026471 | Feb 2009 | WO |
2010077841 | Jul 2010 | WO |
2010127315 | Nov 2010 | WO |
2012012296 | Jan 2012 | WO |
2012103242 | Aug 2012 | WO |
2013013059 | Jan 2013 | WO |
2013075006 | May 2013 | WO |
2013075016 | May 2013 | WO |
2013190337 | Dec 2013 | WO |
2014191263 | Dec 2014 | WO |
2015117001 | Aug 2015 | WO |
2015117005 | Aug 2015 | WO |
2015117026 | Aug 2015 | WO |
2015117032 | Aug 2015 | WO |
2015117036 | Aug 2015 | WO |
2016028796 | Feb 2016 | WO |
2016048721 | Mar 2016 | WO |
Entry |
---|
“ThermaCool Monopolar Capacitive Radiofrequency, The one choice for nonablative tissue tightening and contouring”, Thermage, Inc. Tech Brochure, Nov. 30, 2005, 8 pgs. |
Aguilar et al., “Modeling Cryogenic Spray Temperature and Evaporation Rate Based on Single-Droplet Analysis,” Eighth International Conference on Liquid Atomization and Spray Systems, Pasadena, CA, USA, Jul. 2000, 7 pages. |
Al-Sakere, B. et al. “Tumor Ablation with Irreversible Electroporation,” PLoS One, Issue 11, Nov. 2007, 8 pages. |
Alster, T. et al., “Cellulite Treatment Using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device,” Journal of Cosmetic and Laser Therapy, vol. 7, 2005, pp. 81-85. |
Ardevol, A. et al., “Cooling Rates of Tissue Samples During Freezing with Liquid Nitrogen,” Journal of Biochemical and Biophysical Methods, vol. 27, 1993, pp. 77-86. |
Arena, C. B et al., “High-Frequency Irreversible Electroporation (H-FIRE) for Non-Thermal Ablation Without Muscle Contraction,” BioMedical Engineering OnLine 2011,10:102, Nov. 21, 2011, 21 pgs. |
Becker, S. M et al. “Local Temperature Rises Influence In Vivo Electroporation Pore Development: A Numerical Stratum Corneum Lipid Phase Transition Model,” Journal of Biomechanical Engineering, vol. 129, Oct. 2007, pp. 712-721. |
Bohm, T. et al., “Saline-Enhanced Radiofrequency Ablation of Breast Tissue: an in Vitro Feasibility Study,” Investigative Radiology, vol. 35 (3), 2000, pp. 149-157. |
Bondei, E et al., “Disorders of Subcutaneous Tissue (Cold Panniculitis),” Dermatology in General Medicine, Fourth Edition, vol. 1, Chapter 108, 1993, Section 16, pp. 1333-1334. |
Burge, S.M et al., “Hair Follicle Destruction and Regeneration in Guinea Pig Skin after Cutaneous Freeze Injury,” Cryobiology, 27(2), 1990, pp. 153-163. |
Coban, Y. K. et al., “Ischemia-Reperfusion Injury of Adipofascia I Tissue: An Experimental Study Evaluating Early Histologic and Biochemical Alterations in Rats,” Mediators of Inflammation, 2005, 5, pp. 304-308. |
Del Pino, M. E. et al. “Effect of Controlled Volumetric Tissue Heating with Radiofrequency on Cellulite and the Subcutaneous Tissue of the Buttocks and Thighs,” Journal of Drugs in Dermatology, vol. 5, Issue 8, Sep. 2006, pp. 714-722. |
Donski, P. K et al., “The Effects of Cooling no Experimental Free Flap Survival,” British Journal of Plastic Surgery, vol. 33, 1980, pp. 353-360. |
Duck, F. A., Physical Properties of Tissue, Academic Press Ltd., chapters 4 & 5, 1990, pp. 73-165. |
Duncan, W. C. et al., “Cold Panniculitis,” Archives of Dermatology, vol. 94, Issue 6, Dec. 1966, pp. 722-724. |
Epstein, E. H. et al., “Popsicle Panniculitis,” The New England Journal of Medicine, 282(17), Apr. 23, 1970, pp. 966-967. |
Fournier, L. et al. “Lattice Model for the Kinetics of Rupture of Fluid Bilayer Membranes,” Physical Review, vol. 67, 2003, pp. 051908-1-051908-11. |
Gabriel, S. et al., “The Dielectric Properties of Biological Tissues: II. Measurements in the Frequency Range 10 Hz to 20 GHz,” Physics in Medicine and Biology, vol. 41, 1996, pp. 2251-2269. |
Gage, A. “Current Progress in Cryosurgery,” Cryobiology 25, 1988, pp. 483-486. |
Gatto, H. “Effects of Thermal Shocks on Interleukin-1 Levels and Heat Shock Protein 72 (HSP72) Expression in Normal Human Keratinocytes,” PubMed, Archives of Dermatological Research, vol. 284, Issue 7, 1992: pp. 414-417 [Abstract]. |
Hale, H. B. et al., “Influence of Chronic Heat Exposure and Prolonged Food Deprivation on Excretion of Magnesium, Phosphorus, Calcium, Hydrogen Ion & Ketones,” Aerospace Medicine, vol. 39—No. 9, Sep. 1968, pp. 919-926. |
Heller Page, E. et al., “Temperature-dependent skin disorders,” Journal of the American Academy of Dermatology, vol. 18, No. 5, Pt 1, May 1988, pp. 1003-1019. |
Hemmingsson, A. et al. “Attenuation in Human Muscle and Fat Tissue in Vivo and in Vitro,” Aera Radiologica Diagnosis, vol. 23, No. 2, 1982, pp. 149-151. |
Henry, F. et al., “Les Dermatoses Hivernales,” Rev Med Liege, 54:11, 1999, pp. 864-866. [Abstract Attached]. |
Holland, DB. et al. “Cold shock induces the synthesis of stress proteins in human keratinocytes,” PubMed Journal of Investigative Dermatology; 101(2): Aug. 1993, pp. 196-199. |
Holman, W. L. et al., “Variation in Cryolesion Penetration Due to Probe Size and Tissue Thermal Conductivity,” The Annals of Thoracic Surgery, vol. 53, 1992, pp. 123-126. |
Hong, J.S. et al., “Patterns of Ice Formation in Normal and Malignant Breast Tissue,” Cryobiology 31, 1994, pp. 109-120. |
Huang et al. “Comparative Proteomic Profiling of Murine Skin,” Journal of Investigative Dermatology, vol. 121(1), Jul. 2003, pp. 51-64. |
International Search Report and Written Opinion for PCT/US2007/023492; Applicant: Zeltiq Aesthetics, Inc.; dated May 15, 2008, 7 pages. |
Isambert, H. “Understanding the Electroporation of Cells and Artificial Bilayer Membranes,” Physical Review Letters, vol. 80, No. 15, 1998, pp. 3404-3707. |
Kellum, R. E. et al., “Sclerema Neonatorum: Report of Case and Analysis of Subcutaneous and Epidermal-Dermal Lipids by Chromatographic Methods,” Archives of Dermatology, vol. 97, Apr. 1968, pp. 372-380. |
Koska, J. et al., “Endocrine Regulation of Subcutaneous Fat Metabolism During Cold Exposure in Humans,” Annals of the New York Academy of Sciences, vol. 967, 2002, pp. 500-505. |
Kundu, S. K. et al., “Breath Acetone Analyzer: Diagnostic Tool to Monitor Dietary Fat Loss,” Clinical Chemistry, vol. 39, Issue (1), 1993, pp. 87-92. |
Kundu, S. K. et al., “Novel Solid-Phase Assay of Ketone Bodies in Urine,” Clinical Chemistry, vol. 37, Issue (9), 1991, pp. 1565-1569. |
Kuroda, S. et al. “Thermal Distribution of Radio-Frequency Inductive Hyperthermia Using an Inductive Aperture-Type Applicator: Evaluation of the Effect of Tumor Size and Depth”, Medical and Biological Engineering and Computing, vol. 37, 1999, pp. 285-290. |
Laugier, P. et al., “In Vivo Results with a New Device for Ultrasonic Monitoring of Pig Skin Cryosurgery: The Echographic Cryprobe,” The Society for Investigative Dermatology, Inc., vol. 111, No. 2, Aug. 1998, pp. 314-319. |
Levchenko et al., “Effect of Dehydration on Lipid Metabolism” Ukrainskii Biokhimicheskii Zhurnal, vol. 50, Issue 1, 1978, pp. 95-97. |
Lidagoster, MD et al., “Comparison of Autologous Fat Transfer in Fresh, Refrigerated, and Frozen Specimens: An Animal Model,” Annals of Plastic Surgery, vol. 44, No. 5, May 2000, pp. 512-515. |
Liu, A. Y.-C et al., “Transient Cold Shock Induces the Heat Shock Response upon Recovery at 37 C in Human Cells,” Journal of Biological Chemistry, , 269(20), May 20, 1994, pp. 14768-14775. |
L'vova, S.P. “Lipid Levels and Lipid Peroxidation in Frog Tissues During Hypothermia and Hibernation” Ukrainskii Biokhimicheskii Zhurnal, vol. 62, Issue 1, 1990, pp. 65-70. |
Maize, J.C. “Panniculitis,” Cutaneous Pathology, Chapter 13, 1998, 327-344. |
Malcolm, G. T et al., “Fatty Acid Composition of Adipose Tissue in Humans: Differences between Subcutaneous Sites,” The American Journal of Clinical Nutrition, vol. 50, 1989, pp. 288-291. |
Manstein, D. et al. “A Novel Cryotherapy Method of Non-invasive, Selective Lipolysis,” LasersSurg.Med 40:S20, 2008, p. 104. |
Manstein, D. et al. “Selective Cryolysis: A Novel Method of Non-lnvasive Fat Removal,” Lasers in Surgery and Medicine: The Official Journal of the ASLMS, vol. 40, 2008, pp. 595-604. |
Mayoral, “Case Reports: Skin Tightening with a Combined Unipolar and Bipolar Radiofrequency Device,” Journal of Drugs in Dermatology, 2007, pp. 212-215. |
Mazur, P. “Cryobiology: the Freezing of Biological Systems,” Science, 68, 1970, pp. 939-949. |
Merrill, T. “A Chill to the Heart: A System to Deliver Local Hypothermia Could One Day Improve the Lives of Heart-Attack Patients,” Mechanical Engineering Magazine, Oct. 2010, 10 pages. |
Miklavcic, D et al. “Electroporation-Based Technologies and Treatments,” The Journal of Membrane Biology (2010) 236:1-2, 2 pgs. |
Moschella, S. L. et al., “Diseases of the Subcutaneous Tissue,” in Dermatology, Second Edition, vol. 2, 1985 Chapter 19, Section II (W.B. Saunders Company, 1980) pp. 1169-1181. |
Murphy, J. V. et al., “Frostbite: Pathogenesis and Treatment” The Journal of Trauma: Injury, Infection, and Critical Care, vol. 48, No. 1, Jan. 2000, pp. 171-178. |
Nagao, T. et al.,“Dietary Diacylglycerol Suppresses Accumulation of Body Fat Compared to Triacylglycerol in Men a Double-Blind Controlled Trial,” The Journal of Nutrition, vol. 130, Issue (4), 2000, pp. 792-797. |
Nagle, W. A. et al. “Cultured Chinese Hamster Cells Undergo Apoptosis After Exposure to Cold but Nonfreezing Temperatures,” Cryobiology 27, 1990, pp. 439-451. |
Nagore, E et al., “Lipoatrophia Semicircularis-a Traumatic Panniculitis: Report of Seven Cases and Review of the Literature,” Journal of the American Academy of Dermatology, vol. 39, Nov. 1998, pp. 879-881. |
Nanda, G.S. et al., “Studies on electroporation of thermally and chemically treated human erythrocytes,” Bioelectrochemistry and Bioenergetics, 34, 1994, pp. 129-134, 6 pgs. |
Narins, D.J et al. “Non-Surgical Radiofrequency Facelift”, The Journal of Drugs in Dermatology, vol. 2, Issue 5, 2003, pp. 495-500. |
Nielsen, B. “Thermoregulation in Rest and Exercise,” Acta Physiologica Scandinavica Supplementum, vol. 323 (Copenhagen 1969), pp. 7-74. |
Nishikawa, H. et al. “Ultrastructural Changes and Lipid Peroxidation in Rat Adipomusculocutaneous Flap Isotransplants after Normothermic Storage and Reperfusion,” Transplantation, vol. 54, No. 5, 1992, pp. 795-801. |
Nurnberger, F. “So-Called Cellulite: An Invented Disease,” Journal of Dermatologic Surgery and Oncology, Mar. 1978, pp. 221-229. |
Pease, G. R. et al., “An Integrated Probe for Magnetic Resonance Imaging Monitored Skin Cryosurgery,” Journal of Biomedical Engineering, vol. 117, Feb. 1995, pp. 59-63. |
Pech, P. et al., “Attenuation Values, Volumes Changes and Artifacts in Tissue Due to Freezing,” Acta Radiologica ,vol. 28, Issue 6, 1987, pp. 779-782. |
Peterson, L. J et al., “Bilateral Fat Necrosis of the Scrotum,” Journal of Urology, vol. 116, 1976, pp. 825-826. |
Phinney, S. D. et al., “Human Subcutaneous Adipose Tissue Shows Site-Specific Differences in Fatty Acid Composition,” The American Journal of Clinical Nutrition, vol. 60, 1994, pp. 725-729. |
Pierard, G.E. et al., “Cellulite: From Standing Fat Herniation to Hypodermal Stretch Marks,” The American Journal of Dermatology, vol. 22, Issue 1, 2000, pp. 34-37, [Abstract]. |
Pope, K. et al. “Selective Fibrous Septae Heating: An Additional Mechanism of Action for Capacitively Coupled Monopolar Radiofrequency” Thermage, Inc. Article, Feb. 2005, 6pgs. |
Quinn, P. J. “A Lipid-Phase Separation Model of Low-Temperature Damage to Biological Membranes,” Cryobiology, 22, 1985, 128-146. |
Rabi, T. et al., “Metabolic Adaptations in Brown Adipose Tissue of the Hamster in Extreme Ambient Temperatures,” American Journal of Physiology, vol. 231, Issue 1, Jul. 1976, pp. 153-160. |
Renold, A.E. et al. “Adipose Tissue” in Handbook of Physiology, Chapter 15, (Washington, D.C., 1965) pp. 169-176. |
Rossi, A. B. R. et al. “Cellulite: a Review,” European Academy of Dermatology and Venereology, 2000, pp. 251-262, 12 pgs. |
Rubinsky, B. “Principles of Low Temperature Cell Preservation,” Heart Failure Reviews, vol. 8, 2003, pp. 277-284. |
Rubinsky, B. et al., “Cryosurgery: Advances in the Application of low Temperatures to Medicine,” International Journal of Refrigeration, vol. 14, Jul. 1991, pp. 190-199. |
Saleh, K.Y. et al., “Two-Dimensional Ultrasound Phased Array Design for Tissue Ablation for Treatment of Benign Prostatic Hyperplasia,” International Journal of Hyperthermia, vol. 20, No. 1, Feb. 2004, pp. 7-31. |
Schoning, P. et al., “Experimental Frostbite: Freezing Times, Rewarming Times, and Lowest Temperatures of Pig Skin Exposed to Chilled Air,” Cryobiology 27, 1990, pp. 189-193. |
Shephard, R. J. “Adaptation to Exercise in the Cold,” Sports Medicine, vol. 2, 1985, pp. 59-71. |
SIGMA-ALDRICH “Poly(ethylene glycol) and Poly(ethylene oxide),” http://www.sigmaaldrich.com/materials-science/materialscience-;products.htmi?TablePage=2020411 0, accessed Oct. 19, 2012. |
Smalls, L. K. et al. “Quantitative Model of Cellulite: Three Dimensional Skin Surface Topography, Biophysical Characterization, and Relationship to Human Perception,” International Journal of Cosmetic Science, vol. 27, Issue 5, Oct. 2005, 17 pgs. |
Thermage, News Release, “Study Published in Facial Plastic Surgery Journal Finds Selective Heating of Fibrous Septae Key to Success and Safety of Thermage ThermaCool System,” Jun. 20, 2005, 2 pages. |
Vallerand et al. “Cold Stress Increases Lipolysis, FFA Ra and TG/FFA Cycling in Humans,” Aviation, Space, and Environmental Medicine 70(1), 1999, pp. 42-50. |
Wang, X. et al., “Cryopreservation of Cell/Hydrogel Constructs Based on a new Cell-Assembling Technique,” Sep. 5, 2009, 40 pages. |
Wharton, D. A. et al., “Cold Acclimation and Cryoprotectants in a Freeze-Tolerant Antarctic Nematode, Panagrolaimus Davidi,”, Journal of Comparative Physiology, vol. 170, No. 4, Mar. 2000, 2 pages. |
Winkler, C. et al., “Gene Transfer in Laboratory Fish: Model Organisms for the Analysis of Gene Function,” in Transgenic Animals, Generation and Use (The Netherlands 1997), pp. 387-395. |
Young, H. E. et al. “Isolation of Embryonic Chick Myosatellite and Pluripotent Stem Cells” The Journal of Tissue Culture Methods, vol. 14, Issue 2, 1992, pp. 85-92. |
Zouboulis, C. C. et al., “Current Developments and Uses of Cryosurgery in the Treatment of Keloids and Hypertrophic Scars,” Wound Repair and Regeneration, vol. 10, No. 2, 2002, pp. 98-102. |
Hernan, P. et al., “Study for the evaluation of the efficacy of Lipocryolysis (EEEL)”, Nov. 30, 2011. |
Hernan, R. P., “A Study to Evaluate the Action of Lipocryolysis”, 33(3) CryoLellers, 2012, pp. 176-180. |
Jalian, H. R. et al., “Cryolipolysis: A Historical Perspective and Current Clinical Practice”, 32(1) Semin. Cutan. Med. Surg., 2013, pp. 31-34. |
Zelickson, B et al., “Cryolipolysis for Noninvasive Fat Cell Destruction: Initial Results from a Pig Model”, 35 Dermatol. Sug., 2009, pp. 1-9. |
Disclosure re: “Method and Apparatus for Regional Fat Reduction Using Controlled and Sustained Cooling of Skin Surface,” Oct. 12, 2006, 7 pages. |
Number | Date | Country | |
---|---|---|---|
20150328077 A1 | Nov 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13471826 | May 2012 | US |
Child | 14808245 | US | |
Parent | 11558046 | Nov 2006 | US |
Child | 13471826 | US |